1
|
Ali EAM, Smaida R, Meyer M, Ou W, Li Z, Han Z, Benkirane-Jessel N, Gottenberg JE, Hua G. iPSCs chondrogenic differentiation for personalized regenerative medicine: a literature review. Stem Cell Res Ther 2024; 15:185. [PMID: 38926793 PMCID: PMC11210138 DOI: 10.1186/s13287-024-03794-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Accepted: 06/08/2024] [Indexed: 06/28/2024] Open
Abstract
Cartilage, an important connective tissue, provides structural support to other body tissues, and serves as a cushion against impacts throughout the body. Found at the end of the bones, cartilage decreases friction and averts bone-on-bone contact during joint movement. Therefore, defects of cartilage can result from natural wear and tear, or from traumatic events, such as injuries or sudden changes in direction during sports activities. Overtime, these cartilage defects which do not always produce immediate symptoms, could lead to severe clinical pathologies. The emergence of induced pluripotent stem cells (iPSCs) has revolutionized the field of regenerative medicine, providing a promising platform for generating various cell types for therapeutic applications. Thus, chondrocytes differentiated from iPSCs become a promising avenue for non-invasive clinical interventions for cartilage injuries and diseases. In this review, we aim to highlight the current strategies used for in vitro chondrogenic differentiation of iPSCs and to explore their multifaceted applications in disease modeling, drug screening, and personalized regenerative medicine. Achieving abundant functional iPSC-derived chondrocytes requires optimization of culture conditions, incorporating specific growth factors, and precise temporal control. Continual improvements in differentiation methods and integration of emerging genome editing, organoids, and 3D bioprinting technologies will enhance the translational applications of iPSC-derived chondrocytes. Finally, to unlock the benefits for patients suffering from cartilage diseases through iPSCs-derived technologies in chondrogenesis, automatic cell therapy manufacturing systems will not only reduce human intervention and ensure sterile processes within isolator-like platforms to minimize contamination risks, but also provide customized production processes with enhanced scalability and efficiency.
Collapse
Affiliation(s)
- Eltahir Abdelrazig Mohamed Ali
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1260, Regenerative NanoMedicine (RNM), 1 Rue Eugène Boeckel, 67000, Strasbourg, France
- Université de Strasbourg, 67000, Strasbourg, France
| | - Rana Smaida
- Lamina Therapeutics, 1 Rue Eugène Boeckel, 67000, Strasbourg, France
| | - Morgane Meyer
- Université de Strasbourg, 67000, Strasbourg, France
- Lamina Therapeutics, 1 Rue Eugène Boeckel, 67000, Strasbourg, France
| | - Wenxin Ou
- Université de Strasbourg, 67000, Strasbourg, France
- Centre National de Référence des Maladies Auto-Immunes et Systémiques Rares, Est/Sud-Ouest (RESO), Service de Rhumatologie, Centre Hospitalier Universitaire de Strasbourg, 67000, Strasbourg, France
- Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China
| | - Zongjin Li
- Nankai University School of Medicine, Tianjin, 300071, China
| | - Zhongchao Han
- Beijing Engineering Laboratory of Perinatal Stem Cells, Beijing Institute of Health and Stem Cells, Health & Biotech Co, Beijing, 100176, China
| | - Nadia Benkirane-Jessel
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1260, Regenerative NanoMedicine (RNM), 1 Rue Eugène Boeckel, 67000, Strasbourg, France.
- Université de Strasbourg, 67000, Strasbourg, France.
- Lamina Therapeutics, 1 Rue Eugène Boeckel, 67000, Strasbourg, France.
| | - Jacques Eric Gottenberg
- Université de Strasbourg, 67000, Strasbourg, France.
- Centre National de Référence des Maladies Auto-Immunes et Systémiques Rares, Est/Sud-Ouest (RESO), Service de Rhumatologie, Centre Hospitalier Universitaire de Strasbourg, 67000, Strasbourg, France.
| | - Guoqiang Hua
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1260, Regenerative NanoMedicine (RNM), 1 Rue Eugène Boeckel, 67000, Strasbourg, France.
- Université de Strasbourg, 67000, Strasbourg, France.
| |
Collapse
|
2
|
Davidson MK, Protacio RU, Helmlinger D, Wahls WP. Laboratory horror stories: Poison in the agars. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2024.06.06.597796. [PMID: 38895319 PMCID: PMC11185651 DOI: 10.1101/2024.06.06.597796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/21/2024]
Abstract
The fission yeast Schizosaccharomyces pombe is a single-celled eukaryote that can be cultured as a haploid or as a diploid. Scientists employ mating, meiosis, and the plating of ascospores and cells to generate strains with novel genotypes and to discover biological processes. Our two laboratories encountered independently sudden-onset, major impediments to such research. Spore suspensions and vegetative cells no longer plated effectively on minimal media. By systematically analyzing multiple different media components from multiple different suppliers, we identified the source of the problem. Specific lots of agar, from different suppliers, were toxic. Interestingly, the inhibitory effect was attenuated on rich media. Consequently, quality control checks that use only rich media can provide false assurances on the quality of the agar. Lastly, we describe likely sources of the toxicity and we provide specific guidance for quality control measures that should be applied by all vendors as preconditions for their sale of agar.
Collapse
Affiliation(s)
- Mari K. Davidson
- Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, 4301 West Markham Street (slot 516), Little Rock, AR 72205-7199, USA
| | - Reine U. Protacio
- Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, 4301 West Markham Street (slot 516), Little Rock, AR 72205-7199, USA
| | - Dominique Helmlinger
- Centre de Recherche en Biologie Cellulaire de Montpellier, University of Montpellier, CNRS, 1919 Route de Mende, 34293, Montpellier Cedex 05, France
| | - Wayne P. Wahls
- Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, 4301 West Markham Street (slot 516), Little Rock, AR 72205-7199, USA
| |
Collapse
|
3
|
Barbier MA, Ferland K, De Koninck H, Doucet EJ, Dubourget L, Kim M, Cattier B, Morissette A, Bchetnia M, Larouche D, Kim DH, St-Jean G, Germain L. Cancer Spheroids Embedded in Tissue-Engineered Skin Substitutes: A New Method to Study Tumorigenicity In Vivo. Int J Mol Sci 2024; 25:1513. [PMID: 38338792 PMCID: PMC10855415 DOI: 10.3390/ijms25031513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2023] [Revised: 01/20/2024] [Accepted: 01/23/2024] [Indexed: 02/12/2024] Open
Abstract
Tumorigenic assays are used during a clinical translation to detect the transformation potential of cell-based therapies. One of these in vivo assays is based on the separate injection of each cell type to be used in the clinical trial. However, the injection method requires many animals and several months to obtain useful results. In previous studies, we showed the potential of tissue-engineered skin substitutes (TESs) as a model for normal skin in which cancer cells can be included in vitro. Herein, we showed a new method to study tumorigenicity, using cancer spheroids that were embedded in TESs (cTES) and grafted onto athymic mice, and compared it with the commonly used cell injection assay. Tumors developed in both models, cancer cell injection and cTES grafting, but metastases were not detected at the time of sacrifice. Interestingly, the rate of tumor development was faster in cTESs than with the injection method. In conclusion, grafting TESs is a sensitive method to detect tumor cell growth with and could be developed as an alternative test for tumorigenicity.
Collapse
Affiliation(s)
- Martin A. Barbier
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Karel Ferland
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Henri De Koninck
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Emilie J. Doucet
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Ludivine Dubourget
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - MinJoon Kim
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Bettina Cattier
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Amélie Morissette
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Mbarka Bchetnia
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Danielle Larouche
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Dong Hyun Kim
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
- Department of Dermatology, CHA Bundang Medical Center, CHA University, 59 Yatap-ro, Bundang-gu, Seongnam-si 463-712, Gyeonggi-do, Republic of Korea
| | - Guillaume St-Jean
- Department of Pathology and Microbiology, Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, QC J2S 2M2, Canada;
| | - Lucie Germain
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| |
Collapse
|